Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00785486 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study of Qualaquin and Midazolam
A Phase 1 study, sponsored by Mutual Pharmaceutical Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00785486 is a Phase 1 study that has completed, run by Mutual Pharmaceutical Company. The registered enrollment target is 24 participants.
The verdict
NCT00785486, a Phase 1 study, has completed, sponsored by Mutual Pharmaceutical Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is an open label non-randomized single sequence, single group two way drug interaction study in healthy adult volunteers to determine the extent to which quinine, an inducer of cytochrome p450 CYP 3A4, affects the pharmacokinetics of midazolam, an accepted probe drug for CYP 3A4. The study will also determine the extent to which midazolam affects the pharmacokinetics of quinine.
Interventions
- DRUG Midazolam Alone
- DRUG Qualaquin (quinine) alone steady state
- DRUG Midazolam and Qualaquin at steady state
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-03 |
| Est. Completion | 2007-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00785486
The ClinicalTrials.gov registry entry for NCT00785486 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mutual Pharmaceutical Company, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Midazolam Alone is the first listed.
NCT00785486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00785486 about?
NCT00785486 is a clinical study titled "Drug-Drug Interaction Study of Qualaquin and Midazolam". This is an open label non-randomized single sequence, single group two way drug interaction study in healthy adult volunteers to determine the extent to which quinine, an inducer of cytochrome p450 CYP 3A4, affects the pharmacokinetics of midazolam, an accepted probe drug for CYP 3A4. The study will...
What is the current status of trial NCT00785486?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2007-03. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00785486?
The interventions under investigation include: Midazolam Alone (DRUG), Qualaquin (quinine) alone steady state (DRUG), Midazolam and Qualaquin at steady state (DRUG).
Who is sponsoring clinical trial NCT00785486?
This trial is sponsored by Mutual Pharmaceutical Company, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.